Hammon H M, Zbinden Y, Sauerwein H, Breier B H, Blum J W, Donkin S S
Division of Animal Nutrition and Physiology, Institute of Animal Genetics, Nutrition and Housing, Faculty of Veterinary Medicine, University of Berne, Bremgartenstr. 109a, CH-3012 Berne, Switzerland.
J Endocrinol. 2003 Dec;179(3):427-35. doi: 10.1677/joe.0.1790427.
Glucocorticoids inhibit postnatal growth and yet can stimulate the somatotropic axis around birth. The aim of the present study was to investigate the effects of dexamethasone on the somatotropic axis and on the responses of the insulin-like growth factor (IGF) system to growth hormone treatment in calves. Calves (n=24) were randomly divided into four groups. Group DX was injected with dexamethasone (30 micro g/kg body weight per day), group GH was injected with 500 mg slow-release bovine growth hormone at 14-day intervals, group GHDX was injected with dexamethasone and bovine growth hormone, and group CNTRL (serving as control) was injected with saline from day 3 to day 42 of life. Blood samples were taken on day 3 and blood and liver samples were obtained on days 7, 14, 28 and 42. Body weight increased in the CNTRL and GH groups up to the end of the study and in the DX and GHDX groups up to the fourth week. Dexamethasone treatment decreased (P<0.05) plasma IGF binding protein (IGFBP)-1 on days 7 and 14, but increased (P<0.05) plasma IGFBP-1, decreased (P<0.05) plasma IGF-I and IGFBP-3, and decreased hepatic mRNA for growth hormone receptor (GHR) and IGF-I on day 42. Growth hormone treatment increased (P<0.05) plasma growth hormone concentrations on days 7 and 14, tended to increase (P<0.1) plasma IGF-I concentrations on day 42, and increased (P<0.05) hepatic mRNA levels of GHR on day 14 and IGF-I mRNA levels on days 7 and 14. The combined dexamethasone and growth hormone treatment increased plasma growth hormone concentrations on day 7 and resulted in the highest plasma concentrations of IGF-I and IGFBP-3 (day 7 to day 28) as well as the greatest abundance of hepatic GHR (day 14) and IGF-I (days 7 and 14) mRNA. Plasma IGFBP-1 concentrations in the GHDX group behaved in a similar manner as in the DX group. In conclusion, the response of the somatotropic axis to growth hormone treatment could be greatly enhanced by dexamethasone treatment during the neonatal and early postnatal period, but body weight gain was not improved. Dexamethasone alone inhibited the somatotropic axis and postnatal growth after the first Month of life.
糖皮质激素会抑制出生后的生长,但在出生前后却能刺激生长激素轴。本研究的目的是调查地塞米松对犊牛生长激素轴以及胰岛素样生长因子(IGF)系统对生长激素治疗反应的影响。将24头犊牛随机分为四组。DX组每天注射地塞米松(30微克/千克体重),GH组每隔14天注射500毫克缓释牛生长激素,GHDX组注射地塞米松和牛生长激素,CNTRL组(作为对照)在出生后第3天至第42天注射生理盐水。在第3天采集血样,在第7天、14天、28天和42天采集血样和肝脏样本。到研究结束时,CNTRL组和GH组体重增加,DX组和GHDX组到第四周体重增加。地塞米松治疗在第7天和14天时降低了(P<0.05)血浆IGF结合蛋白(IGFBP)-1,但在第42天时增加了(P<0.05)血浆IGFBP-1,降低了(P<0.05)血浆IGF-I和IGFBP-3,并降低了生长激素受体(GHR)和IGF-I的肝脏mRNA水平。生长激素治疗在第7天和14天时增加了(P<0.05)血浆生长激素浓度,在第42天时血浆IGF-I浓度有增加趋势(P<0.1),在第14天时增加了(P<0.05)肝脏GHR的mRNA水平,在第7天和14天时增加了IGF-I的mRNA水平。地塞米松和生长激素联合治疗在第7天时增加了血浆生长激素浓度,并导致IGF-I和IGFBP-3的血浆浓度在第7天至第28天最高,以及肝脏GHR(第14天)和IGF-I(第7天和14天)的mRNA丰度最高。GHDX组的血浆IGFBP-1浓度变化与DX组相似。总之,在新生儿期和出生后早期,地塞米松治疗可极大增强生长激素轴对生长激素治疗的反应,但体重增加并未改善。单独使用地塞米松会在出生后第一个月后抑制生长激素轴和出生后的生长。